48.52 0.00 (0.00%)
After hours: 5:07PM EDT
|Bid||48.43 x 1400|
|Ask||49.01 x 800|
|Day's Range||48.33 - 49.11|
|52 Week Range||37.47 - 49.78|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.33|
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The acquisition of SuperSonic Imagine is in sync with Hologic's (HOLX) strategy to provide wide-ranging screening, interventional and surgical solutions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...
Hologic, Inc. (HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement with the company and its main shareholders toward that end. “Like our previous acquisitions of Faxitron and Focal, acquiring SuperSonic Imagine will strengthen our strategy to provide comprehensive screening, interventional and surgical solutions across the continuum of breast health care,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. Under the terms of the binding offer, Hologic has agreed to acquire SuperSonic Imagine’s outstanding shares at a price of €1.50 per share.
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
Company’s Costa Rica and Danbury, CT manufacturing facilities recognized for energy savings and operational efficiency initiatives
Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for HOLX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting HOLX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $11.53 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic, Inc. (HOLX) announced today that it has signed an agreement with DEXA+ to distribute Hologic’s Horizon® DXA system for body composition measurement. With over 20 years of experience, DEXA+ works with healthcare practices nationwide to implement and optimize DXA technology to grow integrative medicine, health and wellness programs. The partnership allows Hologic to expand its expertise in body composition assessment and the reach of its market-leading DXA system.
--Improved accuracy in identifying bacterial vaginosis , vulvovaginal candidiasis and trichomoniasis will enable more target
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
Founded in 1978, Kahn Brothers (Trades, Portfolio) & Co. Inc. currently manages more than $800 million in assets. Warning! GuruFocus has detected 3 Warning Sign with BOM:532772. The trade had an impact of -2.24% on the portfolio.
Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.
Company to host timely educational panel on breast density featuring leading clinicians
Hologic CEO Stephen MacMillan explains to Jim Cramer how the company is using technology to address challenges in women's health.